Endocrine Abstracts

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant condition characterized by varying combinations of endocrine tumors and commonly accompanying hyperplasia within the parathyroid gland, anterior pituitary and gastrointestinal tract. Heterozygous germline mutation of the tumor suppressor gene MEN1 is the most common cause of the disease. Molecular genetic testing of menin gene, in which mutation is known to cause MEN1 syndrome, detects pathogenic...

FSH receptor (FSHR) expression has been shown in gonadal tumours, as well as in endothelial tumour vessel cells of various cancers. FSHR, due to its transmembrane localization could be a good candidate for receptor-mediated targeted cancer therapy. In recent years, a number of membrane disrupting lytic peptides have been used for receptor-based cancer therapy. In the present study, we characterised the specificity and cytotoxicity of a lytic peptide Phor21 conjugated to three ...

Progesterone (P4) treatment has been shown to have a clear modulating effect on murine Leydig tumor cell (mLTC-1) function, including downregulation of luteinizing hormone receptor. We hypothesized that P4 would stimulate, whereas an antiprogestine mifepristone (MF) block tumor progression in vivo in a transgenic (TG) murine Leydig cell tumor model (inhibin-α promoter-driven SV40 T-antigen (inhα/Tag)) and act similarly on cell proliferation in vitro...

Antiprogestine mifepristone (MF) has been shown to inhibit ovarian epithelial cancer (OEC) cell growth in vitro and in vivo. Recent clinical trials with MF for human OEC were unsuccessful, for unknown reasons. Progesterone (P4) is believed to have preventive measures towards breast, endometrial or hOEC cancers. Hereby we analyzed the effects of P4 and MF on ovarian granulosa cell tumorigenesis (GCT) in vitro and in vivo...

Expression of the follicle-stimulating hormone receptor (FSHR) has been shown in gonads, gonadal tumors, and in endothelial tumor vessel cells of various cancers. We investigated the specificity and cytotoxicity of a fusion lytic peptide Phor21, conjugated to different FSHβ-chain fragments to ablate FSHR expressing cancer cells in vitro and in vivo. Cytotoxicity of 12 different Phor21-FSHβ conjugates was tested in HEK-293 cells, stably transfected w...

Introduction: Sclerostin, produced by osteocytes, is a potent inhibitor of Wnt signaling and bone formation. The usefulness of its determination in clinical practice is not well established.Objectives: The aims of this study were to evaluate serum sclerostin levels in a cohort of Spanish posmenopausal women, and to analyze its relationship with bone metabolism.Methods: We measured serum sclerostin in 97 posmenopausal women using EL...

Introduction: Thyroid autoimmunity is related to iodine supply. Iodine nutrition has improved in our country, but the prevalence of autoimmune thyroiditis in our children is unknown.Objectives: To determine the status of iodine nutrition in children and adolescents in our city. To calculate local prevalence of thyroid autoimmunity and autoimmune thyroiditis in pediatric ages.Design: Cross-sectional epidemiological study.<p clas...

Background: Pituitary Stalk Interruption Syndrome (PSIS) is a rare congenital anomaly affecting the pituitary gland with characteristic MRI findings of small or absent anterior pituitary gland, misplaced or absent posterior pituitary gland and very thin or interrupted pituitary stalk (1). Patients with PSIS often presents with signs and symptoms of either isolated growth hormone deficiency or multiple anterior pituitary hormone deficiency and symptoms differ according to age a...

Introduction: Heart failure (HF) morbidity and mortality are increasing at an alarming rate in people with type 2 diabetes (T2D). Myocardial dysfunction may develop without ischemic heart disease (IHD), hypertension, or valvular pathologies, and which is defined as diabetic cardiomyopathy (DCM). Although the pathophysiology of DCM is unclear, DCM is initially characterised by myocardial fibrosis, dysfunctional remodelling, and associated diastolic dysfunction, later by systoli...

Background: Alpelisib is an α-selective PI3K inhibitor indicated for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2–), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression or after endocrine therapy. Hyperglycemia is the most common adverse event (up to 60%) associated with its use. It occurs more frequently and lasts longer in patients with pred...